Breaking News: "Pfizer’s Covid Pill Might Not be as Great

New Post Public Reply Private Reply Replies (0) Message Board
JLang brentie #110140
841
Breaking News: "Pfizer’s Covid Pill Might Not be as Great as They’re Saying"

Other shocking headlines.. "Bears Defecate in Highly Wooded Biomes" and "Religious Figures Don Elaborate Headwear"..

Astra Zeneca was pretty low (as in most) on the Sleaze-O-Meter for a long while in this pandemic.. I think Pfizer is on the verge of taking over the top (bottom) spot.

Quote:
The patients in the Merck study and the patients in Pfizer study were drastically different. Merck gave the drug to people who were more than twice as likely to end up in the hospital. Pfizer gave their drug to a healthier population of patients, and, spoiler alert, saw less of them be hospitalized.

Merck’s control arm was hospitalized at 14.1%

Pfizer’s control arm was hospitalized at 7%.

What this means is the real-world efficacy for the Merck drug and the Pfizer drug could be quite similar. In the real world you can’t cherry pick your patients. Covid-19 rips through everyone.

Also: Merck gave their drug to unvaccinated people, while Pfizer hasn’t said whether their participants were vaccinated or not.



Open Menu
Pfizer’s Covid Pill Might Not be as Great as They’re Saying
Nov 5
Written By David Stone

After stating on November 2nd that trial results for their Covid-19 pill might not be out until 2022, Pfizer released results this morning (three days later) touting an 89% reduction in hospitalization.


Merck’s Covid-19 pill (50% reduction in hospitalization with possibly mutagenic side-effects) was an obvious cash grab. Their sales team was scrambling to dump the product and sign deals before better oral treatments were announced. And they would have gotten away with it to, if it wasn’t for that meddling Pfizer. Atea/Roche’s drug flopped in trials, and Pfizer said their data would be delayed by months. This would have given Merck a tiny window to unload their drug. Just yesterday the UK approved molnupiravir, although they’re now probably regretting it.

89% vs 50% sounds like it’s a lot better, right? But here’s the thing. Merck’s trial was a lot different. Pfizer had 45% US patients. Merck only 7%. (We can expect the healthcare given to US patients in a big pharma study to be better than the healthcare given in India.) While not a deal-breaker, this next bit of data is.

Every double-blinded randomly controlled study has a control group. This control group is given a placebo (a pill that does nothing) or the standard of care. When looking for efficacy in a new drug you compare the group that got the new drug to the group that got the placebo or standard of care.

Covid-19 disproportionately affects certain groups. Like people with diabetes, hypertension, asthma, chronic lung disease, severe heart conditions, chronic kidney disease, the obese, or people with weak immune system.

The patients in the Merck study and the patients in Pfizer study were drastically different. Merck gave the drug to people who were more than twice as likely to end up in the hospital. Pfizer gave their drug to a healthier population of patients, and, spoiler alert, saw less of them be hospitalized.

Merck’s control arm was hospitalized at 14.1%

Pfizer’s control arm was hospitalized at 7%.

What this means is the real-world efficacy for the Merck drug and the Pfizer drug could be quite similar. In the real world you can’t cherry pick your patients. Covid-19 rips through everyone.

Also: Merck gave their drug to unvaccinated people, while Pfizer hasn’t said whether their participants were vaccinated or not.



All the headlines are saying “Game changer” or “The beginning of the end of the pandemic.” The reality is, there is still quite a bit of room for improvement. Pfizer’s results might have been near the same, or even worse than Merck’s had they run their trial on actual high-risk patients. If both drugs are approved, a study will be run comparing them against each other. It might even show the Merck drug to be superior.

If Pfizer’s drug trial was run with
Open Menu
Pfizer’s Covid Pill Might Not be as Great as They’re Saying
Nov 5
Written By David Stone

After stating on November 2nd that trial results for their Covid-19 pill might not be out until 2022, Pfizer released results this morning (three days later) touting an 89% reduction in hospitalization.


Merck’s Covid-19 pill (50% reduction in hospitalization with possibly mutagenic side-effects) was an obvious cash grab. Their sales team was scrambling to dump the product and sign deals before better oral treatments were announced. And they would have gotten away with it to, if it wasn’t for that meddling Pfizer. Atea/Roche’s drug flopped in trials, and Pfizer said their data would be delayed by months. This would have given Merck a tiny window to unload their drug. Just yesterday the UK approved molnupiravir, although they’re now probably regretting it.

89% vs 50% sounds like it’s a lot better, right? But here’s the thing. Merck’s trial was a lot different. Pfizer had 45% US patients. Merck only 7%. (We can expect the healthcare given to US patients in a big pharma study to be better than the healthcare given in India.) While not a deal-breaker, this next bit of data is.

Every double-blinded randomly controlled study has a control group. This control group is given a placebo (a pill that does nothing) or the standard of care. When looking for efficacy in a new drug you compare the group that got the new drug to the group that got the placebo or standard of care.

Covid-19 disproportionately affects certain groups. Like people with diabetes, hypertension, asthma, chronic lung disease, severe heart conditions, chronic kidney disease, the obese, or people with weak immune system.

The patients in the Merck study and the patients in Pfizer study were drastically different. Merck gave the drug to people who were more than twice as likely to end up in the hospital. Pfizer gave their drug to a healthier population of patients, and, spoiler alert, saw less of them be hospitalized.

Merck’s control arm was hospitalized at 14.1%

Pfizer’s control arm was hospitalized at 7%.

What this means is the real-world efficacy for the Merck drug and the Pfizer drug could be quite similar. In the real world you can’t cherry pick your patients. Covid-19 rips through everyone.

Also: Merck gave their drug to unvaccinated people, while Pfizer hasn’t said whether their participants were vaccinated or not.



All the headlines are saying “Game changer” or “The beginning of the end of the pandemic.” The reality is, there is still quite a bit of room for improvement. Pfizer’s results might have been near the same, or even worse than Merck’s had they run their trial on actual high-risk patients. If both drugs are approved, a study will be run comparing them against each other. It might even show the Merck drug to be superior.

If Pfizer’s drug trial was run with “high-risk patients” then Merck’s drug trial was run with “extreme risk” patients. Their results shouldn’t be compared as simply as 89% vs 50%. You wouldn’t compare the effectiveness of cancer drugs in patients with stage 2 against a trial run on stage 3 patients, would you?

Of course not.

Gilead still has a chance to redeem themselves here. If you ignore the ease of use (oral vs IV) for a moment and just look at the data, early use of IV remdesivir is similar to the Pfizer pill. Early use of remdesivir reduced hospitalization by 87%.

Pfizer’s 89% comes from patients who were diagnosed within three days.

Gilead’s study allowed for up to seven days. (Antivirals are more effective when given early.)

This means there is still room for improvement in the oral Covid-19 treatment space. Pfizer might have shot themselves in the foot by running a trial against a relatively healthier population. This is bad science and gives vulnerable people false hope.

If you’re at extreme risk of being hospitalized by Covid-19 then it’s unlikely that if you take the Pfizer pill your chance of ending up in the hospital is reduced by 89%. It’s probably a lot lower. Maybe as low as 40-50%. But we won’t know until the drug is out in circulation.

If the Pfizer drug is quickly approved it will set a bad precedent for therapeutics for Covid-19. It will open the floodgates to low-grade trials and outright scams. Companies might even run trials on supremely healthy people. While this won’t fool the FDA, it will lead to pump-and-dump scams.

“Hey, look at our new covid drug, we gave it to 25 Olympic athletes between the ages of 19-23. None of them ended up in the hospital. Efficacy 100%!”

If you’re an investor in a company developing an oral covid-19 treatment, the game isn’t over. Pfizer claims a slam dunk but it appears the net was lowered to seven feet.




CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 78

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Palmer Holland Takes Natural Colors Across North America

Updated Category News Views 27

Natural food color sounds like a tidy little ingredient story until somebody tries to keep a blue beverage blue on a retail shelf. That is where Palmer Holland's new exclusive North American commercial arrangement with BOTANIKind gets interesting. This is not a flashy public-market transaction, and neither company has handed investors a revenue figure, volume target, or...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 47

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
M.O.L.I.F.E. Brings Community Inclusion Into Public View

Updated Category News Views 138

A food pantry can reveal more about inclusion than a polished mission statement ever will. M.O.L.I.F.E., Inc. is set to be featured in an educational segment of All Access with Andy Garcia, and the useful part of this story is not the celebrity-host packaging. It is the organization’s insistence that employment, independent living, day programming, residential support,...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 30

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 74

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 112

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 101

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobile Homes Market Grows to $16.62B by 2031

Updated Category News Views 24

Affordable Housing Fuels Mobile Homes Market When the traditional real estate market is out of reach, what's the average Joe supposed to do? Enter the mobile home market, which is expected to leap from $11.87 billion in 2026 to a hefty $16.62 billion by 2031. That's a compound annual growth rate (CAGR) of 6.96%—not too shabby for a sector often ignored by the mainstream...

Continue Reading
KinderCare Investors Face Legal Challenges Over IPO Misrepresentation

Updated Category News Views 213

Legal Action Against KinderCare Learning Companies A securities class action lawsuit has been initiated against KinderCare Learning Companies, Inc. (NYSE: KLC) and its executives. This lawsuit centers on allegations that the company misrepresented its activities and safety records during its Initial Public Offering (IPO) in October 2024. Investors who acquired KLC common...

Continue Reading
Intec Pharma Ltd's Stock Sees Decline: A Deeper Analysis

Updated Category News Views 204

Intec Pharma Ltd Faces a Rocky Road Intec Pharma Ltd (NASDAQ: INDP) is knee-deep in trouble, with its stock diving to a brutal 52-week low of $1.20. This stark drop of 56.12% over the past year paints a dismal picture for investors scoping out this biotech player. It’s no surprise that all eyes are on INDP as it struggles to navigate these choppy waters and rebuild its...

Continue Reading
Sol Rei Wine Shines at San Francisco Wine Competition

Updated Category News Views 190

Celebrating Excellence at the San Francisco Wine Competition In an impressive display of craftsmanship and quality, Sol Rei Wine has recently achieved remarkable accolades at the esteemed San Francisco Wine Competition. This boutique, women-owned wine brand has won both Double Gold and Gold medals for their exquisite offerings: the Sol Rei Syrah and the Sol Rei Private...

Continue Reading
Insight Molecular Diagnostics Gears Up for Exciting 2026 Launch

Updated Category News Views 260

Exciting Progress Ahead for Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is taking significant strides towards launching its innovative GraftAssureDx™ test in 2026. With anticipation building within the organization and among stakeholders, the company is preparing to submit its application for FDA approval by the year's end. This...

Continue Reading